News 2014-11-03
The general manager attended the CHPI in Paris.
The general manager of Porton, Andrew Xu, together with partial members from BD team, R&D team and Project Management team attended the CHPI which was held in Paris from Oct. 7th to 9th, 2014.
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).
News 2025-04-11
Porton Newsletter - March 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities
